Search results
Results from the WOW.Com Content Network
Midodrine, also known as 3,6-dimethoxy-β-hydroxy-N-aminoethanonyl-2-phenylethylamine, is a substituted phenethylamine derivative. [4] Midodrine is an odorless, white, crystalline powder, soluble in water and sparingly soluble in methanol. [19] Midodrine's experimental log P is -0.5 and its predicted log P ranges from -0.49 to -0.95.
A systematic review and meta-analysis conducted on clinical trials comparing the clinical use of droxidopa and midodrine have found that midodrine was more likely to cause supine hypertension than droxidopa in patients with NOH. Midodrine was also found to be slightly more effective at raising blood pressure but not statistically significantly ...
Desglymidodrine (developmental code name ST-1059) is the active metabolite of the prodrug antihypotensive agent midodrine. [1] [2] [3] It acts as a selective α 1-adrenergic receptor agonist. [1] [2] [3] Desglymidodrine is formed from midodrine via deglycination. [1] [2] [3]
Scientist Otto Warburg, whose research activities led to the formulation of the Warburg hypothesis for explaining the root cause of cancer.. The Warburg hypothesis (/ ˈ v ɑːr b ʊər ɡ /), sometimes known as the Warburg theory of cancer, postulates that the driver of carcinogenesis (cancer formation) is insufficient cellular respiration caused by insult (damage) to mitochondria. [1]
Cancer Causes & Control is a peer-reviewed medical journal published by Springer Science+Business Media, covering research on the epidemiology, causes, and control of cancer. According to the Journal Citation Reports , the journal has a 2020 impact factor of 2.506.
Ionizing radiation may be used to treat other cancers, but this may, in some cases, induce a second form of cancer. [74] Radiation can cause cancer in most parts of the body, in all animals, and at any age, although radiation-induced solid tumors usually take 10–15 years, and can take up to 40 years, to become clinically manifest, and ...
Each patient will be assigned one of the following categories: 1) complete response, 2) partial response, 3) stable disease, 4) progressive disease, 5) early death from malignant disease, 6) early death from toxicity, 7) early death because of other cause, or 9) unknown (not assessable, insufficient data).
A new idea announced in 2011 is an extreme version of multiple mutations, called chromothripsis by its proponents. This idea, affecting only 2–3% of cases of cancer, although up to 25% of bone cancers, involves the catastrophic shattering of a chromosome into tens or hundreds of pieces and then being patched back together incorrectly.